RBC Capital has reaffirmed its "Outperform" rating for BeiGene (ONC, Financial), according to the latest analyst report. The rating has been maintained by Gregory Renza, reflecting continued confidence in the company's performance.
However, a minor adjustment was made to the price target. The price target has been slightly lowered from $312.00 to $311.00, marking a -0.32% change. This adjustment suggests a cautious yet optimistic outlook on the stock's potential growth.
As of the report date, May 8, 2025, BeiGene (ONC, Financial) continues to be viewed favorably by RBC Capital, with the analyst maintaining an "Outperform" stance, indicating that the firm expects the stock to perform better than the broader market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for BeiGene Ltd (ONC, Financial) is $277.93 with a high estimate of $376.00 and a low estimate of $207.00. The average target implies an
upside of 17.45%
from the current price of $236.64. More detailed estimate data can be found on the BeiGene Ltd (ONC) Forecast page.
Based on the consensus recommendation from 24 brokerage firms, BeiGene Ltd's (ONC, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for BeiGene Ltd (ONC, Financial) in one year is $549.01, suggesting a
upside
of 132% from the current price of $236.64. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the BeiGene Ltd (ONC) Summary page.
